Canopy Growth (CGC) Other Accumulated Expenses (2019 - 2026)
Canopy Growth (CGC) reported Other Accumulated Expenses of $6.5 million for Q1 2026, down 63.33% on a YoY basis from $17.7 million in Q1 2025, and down 73.78% sequentially from $24.8 million in Q4 2025.
Canopy Growth (CGC) Other Accumulated Expenses (2019 - 2026) Analysis & Trends
Canopy Growth (CGC) has 8 years of Other Accumulated Expenses data on file, last reported at $6.5 million in Q1 2026.
- For the quarter ending Q1 2026, Other Accumulated Expenses fell 63.33% year-over-year to $6.5 million; the trailing twelve-month figure through Mar 2026 stood at $6.5 million (down 63.33% YoY), and the FY2026 full-year result was $6.5 million, down 63.33% from the prior year.
- Other Accumulated Expenses declined to $6.5 million in Q1 2026, from $24.8 million in the prior quarter.
- In the past five years, Other Accumulated Expenses ranged from a high of $69.3 million in Q1 2023 to a low of $6.5 million in Q1 2026.
- A 5-year average of $34.9 million and a median of $35.7 million in 2024 frame the typical range for Other Accumulated Expenses.
- Peak annual rise in Other Accumulated Expenses reached 190.76% in 2025, while the deepest fall reached 88.7% in 2025.
- Tracing CGC's Other Accumulated Expenses over 5 years: stood at $62.3 million in 2022, then sank by 35.85% to $40.0 million in 2023, then slumped by 78.66% to $8.5 million in 2024, then soared by 190.76% to $24.8 million in 2025, then slumped by 73.78% to $6.5 million in 2026.
- Business Quant data shows CGC's Other Accumulated Expenses at $6.5 million in Q1 2026, $24.8 million in Q4 2025, and $7.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.69 Bn | 87.82 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn |
| 3 | Zoetis | 32.60 Bn | 30.66 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.53 Bn | 23.47 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.06 Bn | 20.91 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - |
| 7 | Viatris | 20.32 Bn | 18.52 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.79 Bn | 16.47 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | Canopy Growth | 275.81 Mn | 9.88 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.50 Mn |
| Dec 31, 2025 | 24.79 Mn |
| Sep 30, 2025 | 6.95 Mn |
| Jun 30, 2025 | 7.22 Mn |
| Mar 31, 2025 | 17.73 Mn |
| Dec 31, 2024 | 8.53 Mn |
| Sep 30, 2024 | 11.95 Mn |
| Jun 30, 2024 | 63.87 Mn |
| Mar 31, 2024 | 35.67 Mn |
| Dec 31, 2023 | 39.96 Mn |
| Sep 30, 2023 | 10.12 Mn |
| Jun 30, 2023 | 48.59 Mn |
| Mar 31, 2023 | 69.35 Mn |
| Dec 31, 2022 | 62.29 Mn |
| Sep 30, 2022 | 61.25 Mn |
| Jun 30, 2022 | 68.20 Mn |
| Mar 31, 2022 | 50.80 Mn |
| Dec 31, 2021 | 63.23 Mn |
| Sep 30, 2021 | 29.96 Mn |
| Jun 30, 2021 | 56.25 Mn |